Bezafibrate in The Treatment of Primary Biliary Cirrhosis: Comparison With Ursodeoxycholic Acid

Kurihara, Toshio; Niimi, Akiko; Maeda, Akiko; Shigemoto, Mutsuo; Yamashita, Katsuko

doi:10.1111/j.1572-0241.2000.03220.x

Cited by 105 publications

(40 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1 study 24 patients were randomly assigned to receive bezafibrate 400 mg/day (n=12) or UDCA 600 mg/day (n=12) for 12 months [6]. Significant reductions in ALT, ALP, γGT and IgM were demonstrated in both treatment groups (p<0.0001); these changes were more pronounced in patients who received bezafibrate [6]. In contrast, in the other study bezafibrate was equally effective with UDCA [15].…”

Section: Discussionmentioning

confidence: 99%

Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study

Liberopoulos¹,

Florentin²,

Elisaf³

et al. 2010

TOCMJ

View full text Add to dashboard Cite

Background:Most patients with primary biliary cirrhosis (PBC) are treated with ursodeoxycholic acid (UDCA); however, some do not respond fully. PBC is also associated with dyslipidemia, but a link with vascular risk has not been confirmed.Methods and Results:In this study we compared UDCA monotherapy with fenofibrate plus UDCA in PBC patients with incomplete biochemical response to UDCA monotherapy for ≥ 8 months. Ten patients (57.2±13.3 years old) with PBC and persistent elevations of liver enzymes after treatment with UDCA (600 mg/day) were randomized to continue UDCA (4 patients) or to receive micronized fenofibrate (200 mg/day) plus UDCA (6 patients) for 8 weeks. Significant reductions in total cholesterol, triglycerides and non-high density lipoprotein cholesterol were observed in the combination treatment group. The serum activities of alkaline phosphatase, gamma-glutamyl transpeptidase and alanine aminotranferase also decreased in this group compared with baseline (-32.6%; p=0.012, -44%; p=0.031 and -16.9%; p=0.029, respectively). In contrast, no significant alterations in liver enzymes or lipid profile were observed in patients who continued UDCA monotherapy. The changes in the lipid and enzyme variables differed significantly (p<0.03) between the 2 groups. Fenofibrate was well tolerated.Conclusions:The administration of fenofibrate plus UDCA seems to be safe and may improve lipid and liver indices in patients with PBC who do not respond fully to UDCA monotherapy. Whether the improved lipid profile translates into a decreased risk of vascular events remains to be established.

show abstract

Section: Discussionmentioning

confidence: 99%

Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study

Liberopoulos¹,

Florentin²,

Elisaf³

et al. 2010

TOCMJ

View full text Add to dashboard Cite

show abstract

“…Other immunosuppressive agents including azathioprine, cyclosporine, mycophenolate mofetil, or methotrexate and drugs with antifibrotic properties including penicillamine, colchicine, and silymarin have not been shown to markedly improve the natural course of the disease or were associated with significant toxicity during long-term treatment [1,[288][289][290][291][292][293][294][295][296].…”

Section: Immunosuppressive Drugsmentioning

confidence: 99%

Primary biliary cirrhosis

2009

View full text Add to dashboard Cite

show abstract

“…Side effects were not observed. In another trial monotherapy with bezafibrate showed a significant reduction in laboratory values, being similar to that seen with the UDCA and bezafibrate combination [92]. It is believed that bezafibrate stimulates phospholipid excretion into bile.…”

Section: Treatment Of Pbcmentioning

confidence: 89%

Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Holtmeier

Leuschner²

2001

Digestion

View full text Add to dashboard Cite

Treatment of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) with ursodeoxycholic acid (UDCA) has been in common use since 1985. In PBC, treatment with UDCA improves laboratory data, liver histology, enables a longer transplantation-free interval and prolongs disease survival. Because UDCA is unable to cure the disease newer drugs or combination therapies are still needed. Studies with UDCA and immunosuppressants such as prednisone, budesonide and azathioprine have shown that in selected patients combination therapy may be superior to UDCA monotherapy. PSC is treated successfully with UDCA and endoscropic dilatation of the bile duct strictures. Treatment of extrahepatic manifestations of cholestatic liver disease such as pruritus, fatigue, osteoporosis and steatorrhea can be problematic and time-consuming.

show abstract

Bezafibrate in The Treatment of Primary Biliary Cirrhosis: Comparison With Ursodeoxycholic Acid

Cited by 105 publications

References 10 publications

Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study

Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study

Primary biliary cirrhosis

Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Contact Info

Product

Resources

About